COSCIENS Biopharma Inc.

The momentum for this stock is not very good. COSCIENS Biopharma Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in COSCIENS Biopharma Inc. .

News

COSCIENS Biopharma crashes on trial setback for lead asset

SeekingAlpha.com: All News COSCIENS Biopharma (CSCI) stock plunged 31% after the company's lead asset, macimorelin, failed to meet the primary endpoint in Phase 3 trial. Read more here.\n more…

Cosciens Biopharma says primary efficacy endpoint of DETECT-trial not met

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Globe Newswire - Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation...\n more…